MedPath

Perindopril

Generic Name
Perindopril
Brand Names
Aceon, Coversyl, Prestalia, Viacoram
Drug Type
Small Molecule
Chemical Formula
C19H32N2O5
CAS Number
82834-16-0
Unique Ingredient Identifier
Y5GMK36KGY

Overview

Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.

Background

Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.

Indication

For the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.

Associated Conditions

  • Cardiovascular Events
  • Diabetic Nephropathy
  • Hypertension
  • Hypertension, Essential Hypertension
  • Myocardial Infarction
  • NYHA Class I Congestive heart failure
  • Stroke
  • Chronic heart failure with reduced ejection fraction (NYHA Class II)
  • Chronic heart failure with reduced ejection fraction (NYHA Class III)

FDA Approved Products

Perindopril Erbumine
Manufacturer:Aurobindo Pharma Limited
Route:ORAL
Strength:4 mg in 1 1
Approved: 2024/03/13
NDC:65862-287
Aceon
Manufacturer:XOMA (US) LLC
Route:ORAL
Strength:8 mg in 1 1
Approved: 2013/01/29
NDC:76234-002
Perindopril Erbumine
Manufacturer:Lannett Company, Inc.
Route:ORAL
Strength:4 mg in 1 1
Approved: 2014/07/03
NDC:0527-1919
Perindopril Erbumine
Manufacturer:Lannett Company, Inc.
Route:ORAL
Strength:8 mg in 1 1
Approved: 2014/07/03
NDC:0527-1920
Prestalia
Manufacturer:Adhera Therapeutics, Inc.
Route:ORAL
Strength:14 mg in 1 1
Approved: 2019/08/31
NDC:72931-012

Singapore Approved Products

TRIPLIXAM FILM COATED TABLET 10 mg/ 2.5 mg/ 10 mg
Manufacturer:Servier (Ireland) Industries Ltd. [SII]
Form:TABLET, FILM COATED
Strength:10 mg
Online:Yes
Approved: 2016/05/23
Approval:SIN15014P
VIACORAM TABLET 14 MG/10 MG
Manufacturer:Servier (Ireland) Industries Ltd., Millmount Healthcare Limited - Site 1 (Primary & Secondary Packager), Millmount Healthcare Limited - Site 2 (Primary & Secondary Packager), Millmount Healthcare Limited - Site 3 (Primary & Secondary Packager)
Form:TABLET
Strength:14 mg
Online:Yes
Approved: 2018/10/01
Approval:SIN15557P
TRIVERAM FILM-COATED TABLET 20 mg/5 mg/5 mg
Manufacturer:Les Laboratoires Servier Industrie [LSI]
Form:TABLET, FILM COATED
Strength:5 mg
Online:Yes
Approved: 2018/02/12
Approval:SIN15427P
COVERAM Tablet 10mg/10mg
Manufacturer:LES LABORATOIRES SERVIER INDUSTRIE [LSI], SERVIER (IRELAND) INDUSTRIES LTD. [SII]
Form:TABLET
Strength:10 mg
Online:Yes
Approved: 2010/07/08
Approval:SIN13827P
AMLESSA TABLETS 4 mg/ 10mg
Manufacturer:Krka, d.d., Novo mesto
Form:TABLET
Strength:4.00 mg
Online:Yes
Approved: 2019/06/27
Approval:SIN15728P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath